Related Experiment Video
Updated: Aug 5, 2026
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
A randomized phase 2 trial of socrodeucitinib in moderate-to-severe plaque psoriasis
Ling Han1, Songmei Geng2, Yangfeng Ding3
1Department of Dermatology, Huashan Hospital, Fudan University, Shanghai, China.
Background:
Tyrosine kinase 2 (TYK2), a key part of the inflammatory cascade responses, plays an integral role in the pathogenesis of psoriasis. Socrodeucitinib, an oral, TYK2 allosteric inhibitor, selectively inhibits TYK2 cytokine signalling pathways in psoriasis pathogenesis.
Objectives:
To evaluate the efficacy and safety of socrodeucitinib in patients with moderate-to-severe plaque psoriasis.
Methods:
In this phase 2, double-blind, placebo-controlled trial, 125 patients were randomly assigned (1:1:1) to receive socrodeucitinib at 6 mg, 12 mg or placebo orally, once daily, for 12 weeks. The primary endpoint was the proportion of patients with a 75% or greater reduction from the baseline in the Psoriasis Area and Severity Index (PASI) score at week 12.
Results:
At week 12, significantly more patients treated with socrodeucitinib achieved a 75% reduction from baseline in PASI score compared with placebo (28.6% at 6 mg, 72.1% at 12 mg vs. 7.5% for placebo, p < 0.05 and p < 0.001, respectively). At the 12 mg dose, socrodeucitinib resulted in significantly higher response rates compared to placebo, with 46.5% of patients achieving PASI 90 (p < 0.001) and 11.6% achieving PASI 100 (p < 0.05). The treatment of socrodeucitinib also led to significantly higher proportions of patients achieving sPGA responses of 0 or 1 compared to placebo: 33.3% at 6 mg and 65.1% at 12 mg versus 10% for placebo (p < 0.05 and p < 0.001, respectively). Most common adverse events included upper respiratory tract infection which demonstrated a certain dose dependency. Most treatment-related adverse events were mild or moderate, and serious adverse events were infrequent, with no clinically meaningful abnormal trend in laboratory parameters.
Conclusions:
Socrodeucitinib demonstrated significantly greater clearing of psoriasis plaques compared to placebo in patients with moderate-to-severe plaque psoriasis and illustrated a favourable safety and tolerability profile, warranting further investigation in longer-duration and larger trials.
Insights
Socrodeucitinib, an oral TYK2 inhibitor, significantly improved moderate-to-severe plaque psoriasis in a Phase 2 trial. The drug demonstrated a favorable safety profile, warranting further investigation.
Area of Science:
- Dermatology
- Immunology
- Pharmacology
Background:
- Tyrosine kinase 2 (TYK2) is implicated in psoriasis pathogenesis.
- Socrodeucitinib is an oral, selective TYK2 allosteric inhibitor targeting psoriasis pathways.
Purpose of the Study:
- To assess the efficacy and safety of socrodeucitinib in patients with moderate-to-severe plaque psoriasis.
Main Methods:
- A Phase 2, double-blind, placebo-controlled trial involving 125 patients.
- Patients received oral socrodeucitinib (6mg or 12mg) or placebo once daily for 12 weeks.
- Primary endpoint: PASI 75 reduction at week 12.
Main Results:
- Significantly more patients achieved PASI 75 with socrodeucitinib (28.6% at 6mg, 72.1% at 12mg) vs. placebo (7.5%).
- Higher PASI 90 and PASI 100 response rates were observed with the 12mg dose.
- Improved sPGA scores were also noted, with favorable safety and tolerability.
Conclusions:
- Socrodeucitinib showed significant plaque clearing in moderate-to-severe psoriasis compared to placebo.
- The drug has a favorable safety and tolerability profile.
- Further long-term, larger trials are warranted.
Related Concept Videos
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
01:11Clinical Trials: Overview
01:29Drugs for Treatment of Ulcerative Colitis in IBD
01:30Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by transmural...